Shares of Inogen, Inc. (NASDAQ:INGN – Get Rating) have been assigned an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $41.00.
A number of research firms have issued reports on INGN. StockNews.com downgraded Inogen from a “hold” rating to a “sell” rating in a research note on Friday, July 8th. Stifel Nicolaus cut their target price on Inogen from $40.00 to $30.00 in a research note on Monday, May 9th.
Hedge Funds Weigh In On Inogen
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arboretum Ventures Inc. bought a new stake in shares of Inogen in the 4th quarter worth approximately $11,220,000. Federated Hermes Inc. raised its holdings in Inogen by 1,774.4% during the 1st quarter. Federated Hermes Inc. now owns 234,502 shares of the medical technology company’s stock valued at $7,603,000 after acquiring an additional 221,991 shares during the period. Invenomic Capital Management LP bought a new stake in Inogen during the 4th quarter valued at $5,624,000. Meros Investment Management LP bought a new stake in Inogen during the 4th quarter valued at $5,090,000. Finally, Rockefeller Capital Management L.P. raised its holdings in Inogen by 35.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 514,425 shares of the medical technology company’s stock valued at $17,489,000 after acquiring an additional 135,799 shares during the period. Hedge funds and other institutional investors own 96.01% of the company’s stock.
Inogen Stock Performance
INGN stock opened at $28.78 on Monday. The company has a market capitalization of $657.22 million, a P/E ratio of -32.70 and a beta of 0.98. Inogen has a 52-week low of $22.51 and a 52-week high of $82.35. The business has a 50-day simple moving average of $25.46 and a two-hundred day simple moving average of $28.84.
Inogen (NASDAQ:INGN – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The medical technology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. The business had revenue of $80.39 million during the quarter, compared to the consensus estimate of $76.56 million. Inogen had a negative return on equity of 3.83% and a negative net margin of 5.64%. The company’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) EPS. As a group, sell-side analysts forecast that Inogen will post -1.61 earnings per share for the current fiscal year.
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Inogen, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Inogen wasn’t on the list.
While Inogen currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.